CD80 and malignant colon neoplasm: A study using in vivo murine breast and colon cancer models showed that anti–PD-L1 (but not anti–PD-1) monotherapy was able to deplete CD80 ligand expression on tumor-infiltrating antigen-presenting cells, thereby inhibiting CTLA-4 axis through a Treg-dependent mechanism (216).